Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
MetadataShow full item record
CitationNishino, Mizuki, Lynette M. Sholl, Hiroto Hatabu, Nikhil H. Ramaiya, and F. Stephen Hodi. 2015. “Anti–PD-1–Related Pneumonitis During Cancer Immunotherapy.” New England Journal of Medicine 373 (3) (July 16): 288–290. doi:10.1056/nejmc1505197.
AbstractThe use of antibodies against programmed cell death 1 (PD-1), which block inhibitory T-cell checkpoints, is a promising new therapy for advanced cancers.1 Recent trials have shown substantial clinical activity of anti–PD-1 antibodies in advanced cancers and led to the approvals of these agents, including pembrolizumab for melanoma and nivolumab for melanoma and squamous-cell lung cancer.2-4 Pneumonitis related to the use of antibodies against PD-1 is an immune-mediated toxic effect that resulted in three drug-related deaths in a phase 1 trial.1 Clinical identification and management of pneumonitis are contingent on radiographic assessment. We report three cases of pneumonitis associated with the use of anti–PD-1 antibodies in patients with melanoma.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32705581
- HMS Scholarly Articles